Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma

The purpose of this project is to evaluate the impact of a 16-week lifestyle program that promotes changes in eating and exercise patterns. The main questions the study will answer are: Do improvements in eating and exercise patterns lead to improved physical function, quality of life and blood biomarkers of biologial aging among individuals with multiple myeloma? Participants will complete study activities 3-4 times during the study. 1. In-person assessment to measure physical function, height/weight, body composition, and includes a blood draw 2. Surveys completed online or on paper at home

Inclusion Criteria: 1. Adult (≥ 18 years) 2. Diagnosed with MM at least one year prior to study enrollment 3. 100 days post transplant (if applicable) 4. Has access to a smart phone or device with internet access 5. Be deemed "clinically stable" by their physician guided by the following: 1. not expected to receive therapies beyond maintenance (for 100 days) 2. no new significant myeloma symptoms (e.g., fractures, spinal stability concerns) meriting changes in anti-neoplastic therapies in the next 30 days; AND 3. stable performance status (ECOG 0-2) assessed in the last 3 months 6. No reports of severe pain \> Grade 3 \[defined by the NCI CTCAE as tumor, neurologic, bone, or other pain interfering with self-care ADLs (bathing, dressing, toileting, continence, feeding)\]. 7. Able to participate in PA and strength training per clinician approval and confirmed by participant 8. Able to understand and willing to sign a written informed consent document 9. English proficient for reading and writing Exclusion Criteria: 1. Coexistent amyloidosis, POEMS syndrome will not be approached 2. Fully adherent to the ACS nutrition and physical activity guidelines 3. If participant is of child-bearing age they cannot be pregnant, planning to come pregnant or lactating during the study period 4. On another interventional clinical trial that precludes co-enrollment 5. Psychiatric or other clinical conditions that preclude study compliance 6. Other important medical or safety considerations at the discretion of the investigator(s) and/or approving clinician